Regeneron Pharmaceuticals Inc. buy Evercore ISI
Summary
This prediction is currently active. With a performance of -1.87%, the BUY prediction by Evercore_ISI is trending in the wrong direction. A total of €0.94 was paid as dividends for this prediction. This prediction currently runs until 22.01.27. The prediction end date can be changed by Evercore_ISI at any time. Evercore_ISI has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | -3.315% | -3.315% |
| iShares Core DAX® | 2.554% | 0.562% |
| iShares Nasdaq 100 | 2.742% | -0.599% |
| iShares Nikkei 225® | 6.584% | 4.336% |
| iShares S&P 500 | 1.930% | -0.507% |
Comments by Evercore_ISI for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Evercore_ISI for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
24.10.24
24.10.25
25.10.25
Regeneron Pharmaceuticals Inc.
16.05.24
16.05.25
17.05.25
Regeneron Pharmaceuticals Inc.
14.05.24
14.05.25
15.05.25

